Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold

Molecular Systems Biology

Volumn 11, Issue 5, 2015, Pages 1-17

  Roux, Jérémie ^a,c   Hafner, Marc ^a   Bandara, Samuel ^a   Sims, Joshua J ^a   Hudson, Hannah ^b   Chai, Diana ^b   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MERRIMACK PHARMACEUTICALS   (United States)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

anti cancer therapeutic antibodies; apoptosis; DR4, DR5 receptors; programmed cell death; TRAIL

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 7; CASPASE 8; FLICE INHIBITORY PROTEIN; INITIATOR CASPASE; MAPATUMUMAB; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; CASP8 PROTEIN, HUMAN; CFLAR PROTEIN, HUMAN; PROTEASOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL FATE; CELL KILLING; CELL POPULATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; HELA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM;

APOPTOSIS; BORTEZOMIB; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL SURVIVAL; HEK293 CELLS; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84930211947     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20145584     Document Type: Article

References (60)

1. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A, (2008) Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 15: 751-761
2. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK, (2008a) Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 30: 11-25
3. Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK, (2008b) Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol 6: 2831-2852
4. Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL, Peter ME, (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 100: 11445-11450
5. Barnhart BC, Alappat EC, Peter ME, (2003) The CD95 type I/type II model. Semin Immunol 15: 185-193
6. Bhola PD, Simon SM, (2009) Determinism and divergence of apoptosis susceptibility in mammalian cells. J Cell Sci 122: 4296-4302
7. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A, (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365
8. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X, (2003) Interdimer processing mechanism of procaspase-8 activation. EMBO J 22: 4132-4142
9. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M, (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124: 601-613
10. Chen JJ, Knudsen S, Mazin W, Dahlgaard J, Zhang B, (2012) A 71-gene signature of TRAIL sensitivity in cancer cells. Mol Cancer Ther 11: 34-44
11. Chi X, Kale J, Leber B, Andrews DW, (2014) Regulating cell death at, on, and in membranes. Biochim Biophys Acta 1843: 2100-2113
12. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, (2010) The BCL-2 family reunion. Mol Cell 37: 299-310
13. Deng Y, Lin Y, Wu X, (2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16: 33-45
14. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A, (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171-185
15. Deveraux QL, Takahashi R, Salvesen GS, Reed JC, (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304
16. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL, (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32: 1341-1350
17. Eskes R, Desagher S, Antonsson B, Martinou JC, (2000) Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935
18. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK, (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 9: 708-714
19. Falschlehner C, Emmerich CH, Gerlach B, Walczak H, (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475
20. Flusberg DA, Roux J, Spencer SL, Sorger PK, (2013) Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell 24: 2186-2200
21. Fricker N, Beaudouin J, Richter P, Eils R, Krammer PH, Lavrik IN, (2010) Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J Cell Biol 190: 377-389
22. Gaudet S, Spencer SL, Chen WW, Sorger PK, (2012) Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Comput Biol 8: e1002482
23. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR, (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2: 156-162
24. Golks A, Brenner D, Krammer PH, Lavrik IN, (2006) The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med 203: 1295-1305
25. Gonzalvez F, Ashkenazi A, (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752-4765
26. Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, Pham VC, Stephan JP, Lill J, Ashkenazi A, (2012) TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell 48: 888-899
27. Hellwig CT, Kohler BF, Lehtivarjo AK, Dussmann H, Courtney MJ, Prehn JH, Rehm M, (2008) Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximide-induced caspase activities during apoptosis initiation. J Biol Chem 283: 21676-21685
28. Hellwig CT, Ludwig-Galezowska AH, Concannon CG, Litchfield DW, Prehn JH, Rehm M, (2010) Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation. J Cell Sci 123: 1401-1406
29. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC, (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647
30. Holland PM, (2014) Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25: 185-193
31. Kataoka T, Tschopp J, (2004) N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol 24: 2627-2636
32. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME, (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588
33. Laussmann MA, Passante E, Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M, (2012) Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling. J Biol Chem 287: 14402-14411
34. Li S, Zhao Y, He X, Kim TH, Kuharsky DK, Rabinowich H, Chen J, Du C, Yin XM, (2002) Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 277: 26912-26920
35. Lopez CF, Muhlich JL, Bachman JA, Sorger PK, (2013) Programming biological models in Python using PySB. Mol Syst Biol 9: 646
36. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X, (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490
37. Majkut J, Sgobba M, Holohan C, Crawford N, Logan AE, Kerr E, Higgins CA, Redmond KL, Riley JS, Stasik I, Fennell DA, Van Schaeybroeck S, Haider S, Johnston PG, Haigh D, Longley DB, (2014) Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly. Nat Commun 5: 3350
38. Martin DA, Siegel RM, Zheng L, Lenardo MJ, (1998) Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem 273: 4345-4349
39. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME, (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16: 2794-2804
40. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O, (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26: 7046-7055
41. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM, (1998) An induced proximity model for caspase-8 activation. J Biol Chem 273: 2926-2930
42. Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, Krammer PH, Lavrik IN, Eils R, (2010) Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol 6: 352
43. Passante E, Wurstle ML, Hellwig CT, Leverkus M, Rehm M, (2013) Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ 20: 1521-1531
44. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S, (2010) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 1805: 123-140
45. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS, Sistonen L, Eriksson JE, (2005) Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 280: 27345-27355
46. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, et al, (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441
47. Rehm M, Dussmann H, Janicke RU, Tavare JM, Kogel D, Prehn JH, (2002) Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 277: 24506-24514
48. Rehm M, Huber HJ, Dussmann H, Prehn JH, (2006) Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 25: 4338-4349
49. Rehm M, Huber HJ, Hellwig CT, Anguissola S, Dussmann H, Prehn JH, (2009) Dynamics of outer mitochondrial membrane permeabilization during apoptosis. Cell Death Differ 16: 613-623
50. Riedl SJ, Salvesen GS, (2007) The apoptosome: signalling platform of cell death. Nat Rev 8: 405-413
51. Scaffidi C, Schmitz I, Krammer PH, Peter ME, (1999) The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274: 1541-1548
52. Shirley S, Micheau O, (2013) Targeting c-FLIP in cancer. Cancer Lett 332: 141-150
53. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F, (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28: 1527-1533
54. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK, (2009) Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428-432
55. Spencer SL, Sorger PK, (2011) Measuring and modeling apoptosis in single cells. Cell 144: 926-939
56. Sun XM, Bratton SB, Butterworth M, MacFarlane M, Cohen GM, (2002) Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 277: 11345-11351
57. Thorpe JA, Christian PA, Schwarze SR, (2008) Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 68: 200-209
58. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A, (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13: 1070-1077
59. de Wilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA, (2013) Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol 85: 363-372
60. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Zannettino AC, Findlay DM, Evdokiou A, (2009) Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 8: 2969-2980